^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Uterine Cancer

    Related cancers:
    17h
    Undifferentiated Carcinoma of the Endometrium: Morphology, Immunophenotype, and Differential Diagnoses to Avoid Diagnostic Pitfalls. (PubMed, Pathol Int)
    These immunophenotypes are not specific because other epithelial and non-epithelial uterine tumors may exhibit overlapping features. Therefore, a comprehensive pathological understanding of UEC is essential for avoiding diagnostic pitfalls and improving diagnostic accuracy.
    Review • Journal
    |
    ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    1d
    Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas (clinicaltrials.gov)
    P=N/A, N=80, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    1d
    QUILT-3.017: Study of NEO-201 in Solid Tumors Expansion Cohorts (clinicaltrials.gov)
    P1/2, N=121, Active, not recruiting, Precision Biologics, Inc | Recruiting --> Active, not recruiting | Trial completion date: Jan 2029 --> Nov 2026 | Trial primary completion date: Jan 2028 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ALK1 (Activin A Receptor Like Type 1)
    |
    PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600
    |
    Keytruda (pembrolizumab) • NEO-201
    1d
    Mesonephric-like adenocarcinoma of the uterine corpus: a case report. (PubMed, Front Med (Lausanne))
    Histopathological examination revealed diverse architectural patterns, including tubular, glandular, and slit-like structures, composed of cells with bland overlapping nuclei and occasional nuclear grooves. Immunohistochemical analysis showed positivity for GATA-3, TTF-1, EMA, and CK, and negativity for ER and PR, supporting the diagnosis of mesonephric-like adenocarcinoma of the uterine corpus.
    Journal
    |
    NKX2-1 (NK2 Homeobox 1) • GATA3 (GATA binding protein 3)
    1d
    Primary Yolk Sac Tumor of the Endometrium: A Case Report and Comprehensive Literature Review. (PubMed, Case Rep Pathol)
    It should be differentially diagnosed from other uterine malignancies. Complete surgical staging combined with chemotherapy may have a better survival impact on endometrial YST.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4)
    2d
    A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification
    |
    Gilotrif (afatinib)
    3d
    ATAD2 suppresses senescence and SASP via SIRT7-p53/p21 to drive progression and immune evasion in endometrial cancer. (PubMed, Clin Epigenetics)
    ATAD2 suppresses cellular senescence and SASP phenotypes via the SIRT7-p53/p21 axis, promoting immune-suppressive TME and driving EC progression and immune evasion. ATAD2 represents a promising therapeutic target for EC.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ATAD2 (ATPase Family AAA Domain Containing 2) • SIRT7 (Sirtuin 7)
    |
    TP53 mutation
    5d
    Molecular and clinicopathological characterisation of SMARCA4-deficient uterine tumours: distinguishing features between dedifferentiated/undifferentiated endometrial carcinoma and undifferentiated uterine sarcoma. (PubMed, Pathology)
    A diagnostic algorithm combining endometrial carcinoma molecular classification, SWI/SNF protein testing, and thorough sampling is proposed. This study expands the clinicopathological and molecular spectrum of SMARCA4-deficient uterine tumours, underscoring the need for entity-specific management strategies.
    Journal
    |
    TP53 (Tumor protein P53) • ARID1A (AT-rich interaction domain 1A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • ARID1B (AT-Rich Interaction Domain 1B) • SOX2 • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2) • SYP (Synaptophysin)
    |
    TP53 mutation
    5d
    Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma. (PubMed, Front Med (Lausanne))
    IHC confirmed PTK6 overexpression as an independent poor prognostic factor for OS (HR = 5.050, 95% CI 2.136-11.943, p < 0.001), associating with aggressive clinicopathological features (all p < 0.05). PTK6 represents a context-dependent prognostic biomarker linked to tumor immune microenvironment remodeling in UCEC, suggesting its potential utility for immunotherapeutic optimization.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PTK6 (Protein Tyrosine Kinase 6)
    |
    MSI-H/dMMR
    6d
    KEYNOTE-E67: A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) (clinicaltrials.gov)
    P1/2, N=40, Completed, Kineta Inc. | Recruiting --> Completed | N=314 --> 40 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • TBS-2025
    6d
    Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management. (PubMed, Front Oncol)
    These preliminary findings suggest that the re-evaluation of biomarkers such as hormone receptors at recurrence may provide valuable guidance for individualized treatment selection (e.g., hormonal therapy). Given the characteristic tendency for late recurrence in LG-ESS, long-term follow-up is essential.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MME (Membrane Metalloendopeptidase) • JAZF1 (JAZF Zinc Finger 1)
    6d
    Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li-Fraumeni syndrome. (PubMed, Histopathology)
    uSMTs exhibit a broad morphologic spectrum in LFS, and multiple molecular alterations may drive tumorigenesis, including MED12, FH, TP53, RB1, ATRX, and a novel ACTG2::BRAF fusion. Although some may be incidental, uSMT in this setting appears enriched for atypical morphology, FH deficiency, and aberrant p53 expression, suggesting an interplay between p53 and FH pathways in tumorigenesis.
    Journal
    |
    BRAF (B-raf proto-oncogene) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • FH (Fumarate Hydratase)
    |
    TP53 mutation • TP53 wild-type • BRAF fusion